PMC:7264098 / 13732-14564 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T252","span":{"begin":0,"end":4},"obj":"DG_47"},{"id":"T253","span":{"begin":64,"end":74},"obj":"SP_7"},{"id":"T254","span":{"begin":132,"end":142},"obj":"SP_7"},{"id":"T255","span":{"begin":205,"end":210},"obj":"UBERON:0000170"},{"id":"T256","span":{"begin":212,"end":216},"obj":"DG_47"},{"id":"T257","span":{"begin":401,"end":405},"obj":"DG_47"},{"id":"T258","span":{"begin":554,"end":558},"obj":"UBERON:0002048"},{"id":"T259","span":{"begin":672,"end":686},"obj":"UBERON:0004535"},{"id":"T260","span":{"begin":793,"end":804},"obj":"UBERON:0002240"},{"id":"T99960","span":{"begin":0,"end":4},"obj":"DG_47"},{"id":"T89902","span":{"begin":64,"end":74},"obj":"SP_7"},{"id":"T78253","span":{"begin":132,"end":142},"obj":"SP_7"},{"id":"T61080","span":{"begin":205,"end":210},"obj":"UBERON:0000170"},{"id":"T66822","span":{"begin":212,"end":216},"obj":"DG_47"},{"id":"T39731","span":{"begin":401,"end":405},"obj":"DG_47"},{"id":"T78045","span":{"begin":554,"end":558},"obj":"UBERON:0002048"},{"id":"T80335","span":{"begin":672,"end":686},"obj":"UBERON:0004535"},{"id":"T48665","span":{"begin":793,"end":804},"obj":"UBERON:0002240"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"312","span":{"begin":64,"end":85},"obj":"Disease"},{"id":"313","span":{"begin":132,"end":152},"obj":"Disease"},{"id":"314","span":{"begin":554,"end":567},"obj":"Disease"},{"id":"315","span":{"begin":576,"end":580},"obj":"Disease"},{"id":"316","span":{"begin":630,"end":656},"obj":"Disease"},{"id":"317","span":{"begin":672,"end":695},"obj":"Disease"},{"id":"318","span":{"begin":738,"end":746},"obj":"Disease"},{"id":"319","span":{"begin":793,"end":811},"obj":"Disease"}],"attributes":[{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"MESH:C000657245"},{"id":"A313","pred":"tao:has_database_id","subj":"313","obj":"MESH:C000657245"},{"id":"A314","pred":"tao:has_database_id","subj":"314","obj":"MESH:D008171"},{"id":"A315","pred":"tao:has_database_id","subj":"315","obj":"MESH:D012128"},{"id":"A316","pred":"tao:has_database_id","subj":"316","obj":"MESH:D001997"},{"id":"A317","pred":"tao:has_database_id","subj":"317","obj":"MESH:D002318"},{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"MESH:D003920"},{"id":"A319","pred":"tao:has_database_id","subj":"319","obj":"MESH:D013119"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T86","span":{"begin":183,"end":191},"obj":"Body_part"},{"id":"T87","span":{"begin":205,"end":210},"obj":"Body_part"},{"id":"T88","span":{"begin":554,"end":558},"obj":"Body_part"},{"id":"T89","span":{"begin":793,"end":804},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma7647"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T23","span":{"begin":554,"end":558},"obj":"Body_part"},{"id":"T24","span":{"begin":793,"end":804},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002240"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T98","span":{"begin":64,"end":72},"obj":"Disease"},{"id":"T99","span":{"begin":64,"end":68},"obj":"Disease"},{"id":"T100","span":{"begin":75,"end":85},"obj":"Disease"},{"id":"T101","span":{"begin":132,"end":140},"obj":"Disease"},{"id":"T102","span":{"begin":132,"end":136},"obj":"Disease"},{"id":"T103","span":{"begin":143,"end":152},"obj":"Disease"},{"id":"T104","span":{"begin":554,"end":567},"obj":"Disease"},{"id":"T105","span":{"begin":576,"end":580},"obj":"Disease"},{"id":"T106","span":{"begin":630,"end":656},"obj":"Disease"},{"id":"T107","span":{"begin":672,"end":695},"obj":"Disease"},{"id":"T108","span":{"begin":738,"end":746},"obj":"Disease"},{"id":"T109","span":{"begin":793,"end":811},"obj":"Disease"},{"id":"T110","span":{"begin":805,"end":811},"obj":"Disease"}],"attributes":[{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0019091"},{"id":"A107","pred":"mondo_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0043797"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T131","span":{"begin":205,"end":210},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T132","span":{"begin":453,"end":454},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T133","span":{"begin":554,"end":558},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T134","span":{"begin":554,"end":558},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T135","span":{"begin":770,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0002421"},{"id":"T136","span":{"begin":770,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0052479"},{"id":"T137","span":{"begin":770,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0052480"},{"id":"T138","span":{"begin":770,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0052483"},{"id":"T139","span":{"begin":770,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0052484"},{"id":"T140","span":{"begin":770,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0052485"},{"id":"T141","span":{"begin":782,"end":786},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"},{"id":"T142","span":{"begin":793,"end":804},"obj":"http://purl.obolibrary.org/obo/UBERON_0002240"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T76","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"T77","span":{"begin":97,"end":365},"obj":"Sentence"},{"id":"T78","span":{"begin":366,"end":832},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":183,"end":197},"obj":"Phenotype"},{"id":"T12","span":{"begin":554,"end":567},"obj":"Phenotype"},{"id":"T13","span":{"begin":672,"end":695},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002088"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"2_test","denotations":[{"id":"32574317-29123544-31466314","span":{"begin":359,"end":363},"obj":"29123544"},{"id":"32574317-30455077-31466315","span":{"begin":598,"end":602},"obj":"30455077"},{"id":"32574317-32292627-31466316","span":{"begin":620,"end":624},"obj":"32292627"},{"id":"32574317-31487104-31466317","span":{"begin":665,"end":669},"obj":"31487104"},{"id":"32574317-25709098-31466318","span":{"begin":709,"end":713},"obj":"25709098"},{"id":"32574317-32291521-31466319","span":{"begin":731,"end":735},"obj":"32291521"},{"id":"32574317-25869301-31466320","span":{"begin":764,"end":768},"obj":"25869301"},{"id":"32574317-30510843-31466321","span":{"begin":782,"end":786},"obj":"30510843"},{"id":"32574317-30362373-31466322","span":{"begin":826,"end":830},"obj":"30362373"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}

{"project":"MyTest","denotations":[{"id":"32574317-29123544-31466314","span":{"begin":359,"end":363},"obj":"29123544"},{"id":"32574317-30455077-31466315","span":{"begin":598,"end":602},"obj":"30455077"},{"id":"32574317-32292627-31466316","span":{"begin":620,"end":624},"obj":"32292627"},{"id":"32574317-31487104-31466317","span":{"begin":665,"end":669},"obj":"31487104"},{"id":"32574317-25709098-31466318","span":{"begin":709,"end":713},"obj":"25709098"},{"id":"32574317-32291521-31466319","span":{"begin":731,"end":735},"obj":"32291521"},{"id":"32574317-25869301-31466320","span":{"begin":764,"end":768},"obj":"25869301"},{"id":"32574317-30510843-31466321","span":{"begin":782,"end":786},"obj":"30510843"},{"id":"32574317-30362373-31466322","span":{"begin":826,"end":830},"obj":"30362373"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"MSCs could be the most promising candidate for the treatment of SARS-CoV-2 infections (Table 1). Since the key for the treatment of SARS-CoV-2 infection lies in the management of the cytokine storm in the lungs, MSCs are well-suited considering their main mechanism of action is through their immunomodulatory and anti-inflammatory properties (Fatima et al., 2017). The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019)."}